Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dihydroergotamine - Impel Pharmaceuticals

Next Previous
Drug Profile

Dihydroergotamine - Impel Pharmaceuticals

Alternative Names: DHE; Dihydroergotamine Mesylate; INP-104; POD-DHE; Trudhesa

Latest Information Update: 19 Jun 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Impel NeuroPharma
  • Developer Impel Pharmaceuticals
  • Class Antimigraines; Ergotamines; Mesylates; Small molecules
  • Mechanism of Action Serotonin 1B receptor agonists; Serotonin 1D receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Migraine

Most Recent Events

  • 26 Apr 2023 Adverse events data from the phase III STOP 301 trial in Migraine presented at the Annual Meeting of American Academy of Neurology (AAN 2023)
  • 25 Apr 2022 Impel Neuropharma is now called Impel Pharmaceuticals
  • 30 Sep 2021 Planned Prescription Drug User Fee Act (PDUFA) date for Migraine in USA (Intranasal) is 2021-09-06

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top